Last reviewed · How we verify
Cenicriviroc in moderate liver impaired — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cenicriviroc in moderate liver impaired (Cenicriviroc in moderate liver impaired) — Tobira Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cenicriviroc in moderate liver impaired TARGET | Cenicriviroc in moderate liver impaired | Tobira Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cenicriviroc in moderate liver impaired CI watch — RSS
- Cenicriviroc in moderate liver impaired CI watch — Atom
- Cenicriviroc in moderate liver impaired CI watch — JSON
- Cenicriviroc in moderate liver impaired alone — RSS
Cite this brief
Drug Landscape (2026). Cenicriviroc in moderate liver impaired — Competitive Intelligence Brief. https://druglandscape.com/ci/cenicriviroc-in-moderate-liver-impaired. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab